CSF1 gene fusions with COL6A3 and S100A10 are commonly observed in tenosynovial giant cell tumors (incidence rate of 50%-64%), and CSF1 gene breakpoint probes are helpful for diagnosing such tumors;

The diagnosis of tenosynovial giant cell tumors is typically straightforward. The most important differential diagnosis to consider is diffuse tenosynovial giant cell tumor (which has a significantly higher local recurrence rate).